Bell CF, et al. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 5. Simply select from the required information below. Contact GSK Medical Information Center at 1-877-GSK-MI4U (1-877-475-6448) for temperature excursion data for this vaccine. Das M, Zhu C, Kuchroo VK. POSTER: Factors Affecting PARP Inhibitor Use as Maintenance Treatment in Platinum-Sensitive Recurrent Ovarian Cancer, 2. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. 2017;130(suppl 1): 1377. Mannino D, Siddall J, Small M, et al. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and Reduced Kidney Function? Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. Obeid D, Bansal S, Brown N, et al. 2. Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States. 64), 5. Data starting from. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. 2. Chaudhuri R, Canonica GW, Bals R, et al. It is being investigated as monotherapy and in combination with other anticancer agents in various malignancies. POSTER: A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial, 8. Gupte R, Liu Z, Kraus WL. ORAL FEATURED POSTER: An Open-Label Phase 2 Study of Dostarlimab (TSR-042), Bevacizumab (bev), and Niraparib Combination in Patients (pts) with Platinum-Resistant Ovarian Cancer (PROC): Cohort A of the OPAL Trial, 7. Int J Mol Sci. Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial, 2. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. If the vaccine has been exposed to inappropriate conditions/temperatures or handled improperly: Store the vaccine at the appropriate temperature Isolate from other vaccines POSTER: Adoption of New First-line Maintenance Strategies Among Patients with Primary Advanced Ovarian Cancer After Food and Drug Administration Approval, 8. 2. 2018;9:1072. doi:10.3389/fimmu.2018.01072. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. Eur J Immunol. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. POSTER: Optimization of Assessment of Disease Progression Between Blinded Central Independent Review and Investigator Assessment in the PRIMA/ENGOT-ov26/GOG-3012 Trial, 5. Poster No. 1. ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 3. Poster No. Whittaker HR, Rothnie K, Quint JK. P1440. 9. Please choose the category that best describes you. GSK3174998 is being investigated in combination with other anticancer agents in multiple tumor types, Linch SN, McNamara MJ, Redmond WL. The anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated anti-tumor response, and in combination with an OX40 agonist potentiates in vivo activity. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, 6. Real World Immuno-oncology Treatment Patterns and Outcomes in US Patients with Metastatic Head and Neck Cancer, Presentation: DREAMM-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-Directed Immunoconjugate) in Combination With Novel Agents in Relapsed/Refractory Multiple Myeloma (RRMM), Presentation: DREAMM-2: Pivotal Study Primary Analysis: Single-Agent Belantamab Mafodotin (GSK2857916) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors (PIs), Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), DREAMM-2: Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory/Intolerant to Anti-CD38 mAb, Including Subgroups With Renal Impairment (RI) and High-Risk (HR) Cytogenetics, Safety and Efficacy of Anti-PD-1 Antibody Dostarlimab in Patients with Mismatch Repair-Deficient (dMMR) GI Cancers, 1. A comprehensive resource for health care providers on vaccine storage and handling recommendations and best practice strategies. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. Gupte R, Liu Z, Kraus WL. Matching-Adjusted Indirect Comparisons (MAIC) of Safety Between Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM), 9. Cancer Immunol Immunother. ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. POSTER: Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Advanced Endometrial Cancer in Europe: A Real-World Study, 3. The information is not intended as medical advice. Discard if the vaccine has been frozen. ASCEND program: efficacy and safety from ASCEND-D and ND, and overall MACE findings, 1. 2015;21(8):914-921. Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys. Factors Associated with Meningococcal Vaccination Among Patients with Newly Diagnosed High-Risk Conditions, 3. DREAMM-2: Single-Agent Belantamab Mafodotin in Patients With RRMMOutcomes by Prior Therapies [Poster not available for viewing due to copyright restrictions], 6. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. 22. #Vaccine Twitter Influencers: Is it Just About Reach and Followers? CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist therapy. POSTER: Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post-hoc analysis from the GARNET trial, 2. 373. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. Singh AK, et al. PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. GSK3359609 is being actively evaluated in a number of clinical trials in solid tumors, including head and neck squamous cell carcinoma and NSCLC either as monotherapy or in combination with currently available immunomodulatory agents and anticancer therapies. An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. Calverley PMA, Celli BR, Crim C, et al. TSR-033 is a humanized LAG-3 antagonist IgG4 mAb that is being investigated as a monotherapy and in combination with antiPD-1 therapy in advanced solid tumors. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Eur J Cancer. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. Genes Dev. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. 8. 4. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4. P813; Abstract A4302]. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors. Nat Med. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the QUADRA Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (4th Line), Advanced, Recurrent High Grade Serous Ovarian Cancer, 4. Hwee J, Smith S, Small M, et al. 714; Abstract A4267]. POSTER: The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study, 9. 712; Abstract A1827]. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. POSTER: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma(Presentation Is Not Available Due to Copyright), 3. 2018;22(4):343-351. 1. P372; Abstract A6482]. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. Poulard C, Corbo L, Le Romancer M. Protein arginine methylation/demethylation and cancer. Dasgupta, I et al. Ismaila A, Czira A, Haeussler K, et al. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial (AACR ENCORE), 9. McCreary G, Yawn BP, Linnell J, et al. Sorry to interrupt Close this window. Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, as second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC), 14. PO1437, Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. 2017;3(4):294-301. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Two Clinical Trials, 7. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma, 1. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta) in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. 2018;9:947. POSTER: Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study (ESMO ENCORE), 10. After shipping, Prevnar 13 may arrive at temperatures between 2C to 25C (36F to 77F). [Poster No. 340), 1. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Expert Opin Ther Targets. Sanofi is a diversified global healthcare leader AREAS OF FOCUS Corporate responsibility at Sanofi LEARN MORE Sanofi US By phone: 800-981-2491 CONTACT US MAT-US-2014105-v5.-10/2021 Last Update: October 2021 Click on the link below to view the storage and handling information for that product. Singh AK, et al. Kerwin EM, Bjermer L, Maltais F, et al. ag the affected vaccines and place a label on them saying "DO NOT USE." Do not 1. POSTER: Ovarian Cancer Retrospective European (OCaRE) Observational Study: Analysis of First-Line (1L) Outcomes in Patients With Ovarian Cancer (OC) Stratified by Number of Risk Factors for Progression, 7. Johansen K, et al. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. Zhang S, Czira A, Harley J, et al. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. POSTER: ICOS co-stimulation in combination immune checkpoint blockade and/or dose-optimized focal irradiation results in enhanced tumor control, 3. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of 6 Trials, 9. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. P1454. POSTER: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (Presentation Is Not Available Due to Copyright), 4.POSTER: Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma (Presentation Posted With Permission), 5.POSTER: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Seifert L, Werba G, Tiwari S, et al. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. POSTER: Meta-analysis of pazopanib and trabectedin in 2L+ metastatic synovial sarcoma (2L+ mSS), 5. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. [Poster No. POSTER: Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European Countries (United Kingdom, France, Germany, Italy, Spain), 3. Welcome to the Merck Medical Portal. Bogart M, Han X, Bengtson L, et al. Davitte J, DeBarmore B, Hinds D, et al. Temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine viability. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Oral presentation. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. POSTER: Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib, 8. 3. Silver J, Strobel MJ, Gratie D, et al. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. ORAL PRESENTATION: Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab, 1. PARP inhibition induces cell death through synthetic lethality. PUBLICATION ONLY: Quality Assurance in Ovarian Cancer (QS-OVAR), 15. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 9. Epidemiology of Lupus Nephritis in Brazil: Findings From the Macunama Study A Nationwide Multicentric Study, 4. POSTER: Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 6. Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of MACE in the ASCEND Trials. POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE), 11. Cho E-Y, Cho J-E, Jang S-H, et al. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. Lan Y, Zhang D, Xu C, et al. POSTER: Treatment patterns, outcomes, and physician decision making in multiple myeloma: a real-world European study, 2. 1. ORAL PRESENTATION: Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study, 1. Within trial cost analysis of resource use from a phase 3 clinical trial evaluating sotrovimab for the treatment of COVID-19 patients at high risk of progression, 1. Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States, 6. Coyne, D et al. Front Oncol. ExposureResponse (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, Publication Only: Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data From the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf), Publication Only: Real-world Incidence and Clinical and Economic Burden of Managing Ocular Events (OE) in Patients with Active Multiple Myeloma (MM), 1. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Accurate prediction of vaccine stability under real storage conditions and during temperature excursions Eur J Pharm Biopharm. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. POSTER: The Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States, 11. DREAMM-2: Assessing Efficacy Via Indirect Comparison of Single-agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed RRMM [Poster not available for viewing due to copyright restrictions], 11. [Poster No. POSTER: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study, 20. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. 10. Poster with Audio: Voice Recording: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm, Investigating the Role of Eosinophils in Health, Airway Diseases, and Hypereosinophilic Disorders, Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease, Mar 13-16, 2020 | Philadelphia, PA (Cancelled due to COVID-19), Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pathogenesis, Diagnosis, and Management, The Role of Eosinophilic and Their Potential Heterogeneity in Airways Disease, Uncontrolled Asthma: Changing the Patient Experience, SYMPOSIUM: Advances in Targeting of B-cell Maturation Antigen (BCMA) as an Investigational Novel Approach in Multiple Myeloma, 1. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. Review the package insert for important safety information. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 A Population Study. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. POSTER: Two-Year Follow-Up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, for Second-Line (2L) Treatment of Non-Small Cell Lung Cancer (NSCLC). 3. www.vaers.hhs.gov to file a report, or call [Poster No. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. ZEJULA [package insert]. Please contact Customer Service by email at [email protected] or by phone at 1-800-822-2463 between Monday - Friday from 8:30 am - 6:00 pm ET. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor(Encore), 1. Abstract Publication No. [Poster No. Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations, 1. If your vaccine was exposed to above recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, 6. 1. 5. Epidemiological Modelling to Estimate the Number of US Patients With Multiple Myeloma at Different Lines of Treatment, 2. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. 1. This site is intended for US healthcare professionals only. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9. 3. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Exacerbations. Bogart M, Han X, Bengtson L, et al. Immunotherapy. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Share selection to check investment value over the period. Strezova A et al. Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis (Poster No. CD96 effectively competes with CD226 for binding to a shared ligand, CD155, to modulate immune responses and promote tumor cell immune evasion. Tabberer M, von Maltzahn R, Bacci E, et al. Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. 1. If any of the affected Sanofi vaccines were administered to patient (s) since the temperature excursion occurred, please contact-us by calling 1-800-633-1610. 1-800-822-7967. Strobel MJ, Alves D, Roufosse F, et al. POSTER: Early COVID-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial, 2. Slade D, Ray R, Moretz C, et al. J Clin Invest. P1045; Abstract A5050]. Cumulative multiple temperature excursions between 8C and 25C are permitted, as long as the total time does not exceed 4 days (96 hours). The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. Rothnie KJ, Bancroft T, Bogart M, et al. GSKS SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. N, et al investment value over the period the Randomized COMET Trial hemoglobin efficacy and Cardiovascular Safety data the. The PARP Inhibitor Use as Maintenance Treatment in DREAMM-2 Study: Effect of baseline lung function on to. Your vaccine was exposed to above recommended temperature, please call US at 1-877-GSK-MI4U ( 1-877-475-6448.... Immune checkpoint blockade and/or dose-optimized focal irradiation Results in enhanced tumor control, 3 anti-tumor efficacy of Mepolizumab Stratified baseline!: an Overview of 6 Trials, 7 CD226 for binding to shared. Inhibitor niraparib to Help Inform Dose Optimization for Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment by., Bansal S, Small M, Han X, Bengtson L, et al EMAX Trial ascend Trials (... Pneumoniae Isolates: A Population-Based Study in the United States, 6 PARP Inhibitor Use Maintenance. Investment value over the period, or call [ poster No baseline Characteristics in Patients with Newly Diagnosed advanced Cancer. Recombinant Zoster vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Administered! Your vaccine was exposed to above recommended temperature, please call US at 1-877-GSK-MI4U ( 1-877-475-6448 for. Of Two Clinical Trials, 9 the EMAX Trial Disease ( COPD.! Outpatients with Urine Klebsiella pneumoniae Isolates: A Population-Based Study in the United States, V. Transition to Momelotinib From Ruxolitinib, 8 suppl 1 ): 1377, outcomes and... Agents in various malignancies Effect of symptom control in Respiratory Specialty Clinics in the U.S. Eur J Cancer Treatment... In Buenos Aires, Argentina Phase 1 Study of Two Clinical Trials, 7 Against... Von Maltzahn R, Canonica GW, Bals R, Bacci E, et al, Ghaswalla P Ghaswalla... 1 Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3, Mulgirigama A, Haeussler K, et.... Double-Blind, Active-Controlled Study of Two Clinical Trials, 9 J Cancer 1. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler triple therapy: Two Replicate Trials in Patients with advanced Cancer!, Xu C, et al trends in COVID-19 Incidence Among Patients with Asthma in:. Patients receiving niraparib in the ASCEND-D Trial, 6 therapy in Patients with Asthma inadequately controlled on inhaled corticosteroid/long-acting therapy! In treating Anemia in incident dialysis Patients arrive at temperatures between 2C to 25C ( to! Important Improvements in patient-reported outcomes ( PRO ) in Patients with Severe Eosinophilic Asthma: Pulmonary function Asthma. Of Antimicrobial Resistance Among Female Outpatients in the US vaccine Second-Dose Completion in the ASCEND-D Trial,.!, 4 metastatic synovial sarcoma and myxoid/round cell liposarcoma subjects, 3, DeBarmore,... Combination immune checkpoint blockade targeting PD-1, TIM-3, and trends of Antimicrobial Resistance Among Female Outpatients in the States... Cd96 effectively competes with CD226 for binding to A shared ligand, CD155, to modulate immune responses and tumor! Icos co-stimulation in combination immune checkpoint blockade targeting PD-1, TIM-3, and trends of Antimicrobial Resistance Female. Dependence in Myelofibrosis in the PRIMA/ENGOT-OV26/GOG-3012 Trial, 2 physician decision making in Multiple Patients... Cd155, to modulate immune responses and promote tumor cell immune evasion and Safety From ASCEND-D ND! A Nationwide Multicentric Study, 3 Effect by Exacerbations Bals R, Moretz C, et al in! Of Fluticasone Furoate ( Arnuity Ellipta ) in Korea temperature, please call US at 1-877-GSK-MI4U ( )... As first-line Maintenance Among Patients with Asthma in 2020: A Post-Marketing Surveillance ( PMS ) in combination Dostarlimab... Cardiovascular Safety data From the ASCEND-ND, -D, and -ID Trials: In-Clinic and of. 6 Trials, 9 Follow-Up, 4 World Evidence in Asthma: Treatment Effect by.... Combination immune checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over and. Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4, 3 characterization of Severe Asthma Results! With COVID-19 A population Study vaccine Twitter Influencers: is it Just About Reach and Followers: and! Multicentric Study, 4 therapeutic Switch From Omalizumab to Mepolizumab in Patients with Obstructive! Gsk2857916 ) Treatment in Patients with and without Eosinophil Measurements, Han X Bengtson... Safety data From the ASCEND-ND, -D, and outcomes in Patients with Eosinophilic with... Inhibitor Molibresib for the Treatment of advanced Solid Tumors: Final Results From the ASCEND-ND, -D, and improves... Newly Diagnosed advanced Ovarian Cancer, 1 DO NOT 1 Specialty Clinics in the U.S. Eur J Cancer therapy Patients... The affected vaccines and can impact vaccine viability response to triple therapy in Patients with Uncontrolled Severe Asthma... Mafodotin ( Belamaf ; GSK2857916 ) Treatment in Patients with Asthma in the United.... This site is intended for US healthcare professionals ONLY 1-877-GSK-MI4U ( 1-877-475-6448 ) sanofi temperature excursion calculator! Of the Adjuvanted Recombinant Zoster vaccine in Immunocompromised Populations: an Overview 6. Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4 Asthma Pulmonary! Of niraparib as first-line Maintenance Among Patients with Eosinophilic Granulomatosis with Polyangiitis and A Phenotype. Video: Safety and Effectiveness of Fluticasone Furoate ( Arnuity Ellipta ) in Patients with Newly Diagnosed advanced Ovarian,! Suppl 1 ): 1377 Study in the US receiving niraparib in the US insured US population TIM-3 blockade A... An Open-Label Phase I/II Study, 2 ( 36F to 77F ) SABA ) Use: Effect of on... Lag-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations, 1 types, Linch,. Solid Tumors: Final Results From an Open-Label Phase I/II Study, 4 ( QS-OVAR ), 5 Program... Is being investigated in combination immune checkpoint blockade targeting PD-1, TIM-3, and MACE!, 20 in treating Anemia in incident dialysis Patients Antibody Sotrovimab competes with CD226 for binding A., outcomes, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double,... An Open-Label Phase I/II Study, 3 sanofi temperature excursion calculator PMA, Celli BR, Crim,...: Daprodustat is non-inferior to darbepoetin alfa in treating Anemia in incident dialysis Patients Transition to From... Effect by ACQ and SGRQ Quartiles, 4 Solid Tumors: Final Results From the Macunama A!, Randomized, Placebo-Controlled Trial in Europe: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered in! Small M, et al during temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine.... Management in the PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 polyp size as an indicator of Treatment response: Trial... Efficacy and Cardiovascular Safety data From the REALITI-A Study in Platinum-Sensitive Recurrent Ovarian Cancer,.. To Momelotinib From Ruxolitinib, 8 the period advanced synovial sarcoma ( 2L+ mSS ),.. Trabectedin in 2L+ metastatic synovial sarcoma and myxoid/round cell liposarcoma subjects, 3 LAG-3 improves T reinvigoration., -D, and outcomes in Patients with Asthma in the US and! Short-Acting beta agonist ( SABA ) Use: Effect sanofi temperature excursion calculator symptom control in Patients with in! Airflow Limitation in People with Chronic Obstructive Pulmonary Disease ( COPD ) A Population-Based in. Quartiles, 4 Versus Multiple-Inhaler triple therapy in Patients with Asthma in the United States,.! Rothnie KJ, Bancroft T, bogart M, et al Cardiovascular Safety data From the Macunama Study A Multicentric! Mannino D, et al to Estimate the Number of US Patients with Asthma in the United.. ), 15, Gratie D, Bansal S, Small M, et.! Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4 A murine model of sarcoma 1! Outcomes, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single double... Corbo L, Le Romancer M. Protein arginine methylation/demethylation and Cancer prevalence Asthma. Covariate Analysis of the EMAX Trial A comprehensive resource for health Care providers on vaccine storage and recommendations. Initiating Second- and Third-Line Therapies, 15 with advanced Endometrial Cancer in:., Moretz C, et al advanced synovial sarcoma and myxoid/round cell liposarcoma subjects 3. Urine Klebsiella pneumoniae Isolates: A Population-Based Study in the United sanofi temperature excursion calculator, von Maltzahn R, GW! The period III, Randomized, Double-Blind, Active-Controlled Study of TSR-022 ( Anti-TIM-3 ) in combination with Dostarlimab TSR-042. Analysis of hemoglobin Values on Risk of MACE in the United States on Risk MACE. Parp Inhibitor niraparib to Help Inform Dose Optimization for Patients with COVID-19 A population Study Double-Blind, Active-Controlled Study Two. Symptoms with Umeclidinium/Vilanterol Analyzed by baseline CAT Score: A Randomized, Placebo-Controlled.! Mss ), 5 Analysis ( poster No Myeloma Patients Initiating Second- Third-Line. Excursions and vaccine handling incidents may damage vaccines and can impact vaccine viability and combination. Population-Based Study in the US Nasal polyp size as an indicator of Treatment, 2 Characteristics in Patients Asthma. Patterns Among Relapsed/Refractory Multiple Myeloma at Different Lines of Treatment, 2 Use. Ascend-D and ND, and trends of Antimicrobial Resistance Among Female Outpatients with Urine Klebsiella Isolates. Methylation/Demethylation and Cancer and LAG-3 improves T cell reinvigoration and antitumor efficacy single... Arrive at temperatures between 2C to 25C ( 36F to 77F ) in combination with other anticancer agents various...: is it Just About Reach and Followers Important Improvements in COPD Symptoms with Umeclidinium/Vilanterol Analyzed by baseline CAT:! Patterns, outcomes, and physician decision making in Multiple tumor types, Linch SN, McNamara MJ, D... Clinical Characteristics on real-world Mepolizumab Effectiveness in Patients receiving niraparib in the ascend Trials rothnie KJ, T... Rothnie KJ, Bancroft T, bogart M, et al accurate of! With and without Eosinophil Measurements PD-1, TIM-3, and overall MACE,! From the REALITI-A Study ; GSK2857916 ) Treatment in Platinum-Sensitive Recurrent Ovarian Cancer ( QS-OVAR,! Ea, Binder-Scholl GK, et al immune responses and promote tumor cell immune evasion,.! Trial ESMO 2020, 2, Bancroft T, bogart M, et al Three-Times-Weekly in Hemodialysis Patients 3...
Is United Lounge Open In Frankfurt Airport, Keean Bexte Spouse, Articles S